USPTO serial 79342263
ILLIMIS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 4, 2023
- Examiner
- THOMAS, JULIE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ILLIMIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jong Park
Jong Park The PL Law Group, PLLC13800 Coppermine Rd., FL1-3The PL Law Group, PLLCHerndon, VA 20171Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical agents affecting sensory organs; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for activating cellular function; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for respiratory organs; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of inflammatory diseases; ophthalmic preparations; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of degenerative brain disease; pharmaceutical preparations for the treatment of brain dysfunction; pharmaceutical preparations for the treatment of stroke; pharmaceutical preparations for the treatment of cerebrovascular disease; pharmaceutical preparations for the treatment of dementia; pharmaceutical preparations for the treatment of Alzheimer's disease; pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders, amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders | ACTIVE | — |
| 042 | Pharmaceutical product development; pharmaceutical research and development of medicines in the field of age-related diseases/disorders and degenerative diseases; pharmaceutical research and development of medicines in the field of chronic malady/disease and dysfunction; scientific research for medical purposes in the field of gene therapy; medical scientific research in the field of brain disease; medical scientific research in the field of neurological diseases; biotechnology research and scientific and pharmaceutical research in the antibody field; biological research; scientific research in the field of cancer disease; remote monitoring and quality control inspection for others of active substances in the pharmaceutical research field and scientific analysis of active substances in the pharmaceutical research field; research for quality inspection related to human hygiene management for medical research purposes; scientific and medical research of autoimmune disease; development of pharmaceutical preparations for cell therapy; stem cell collection for medical research; cell processing and culture for medical research; pharmaceutical research and development of medicines in the field of inflammatory disease; pharmaceutical research and development of medicines in the field of eye disease; pharmaceutical research and development of medicines in the field of amyloidosis; consultancy pertaining to pharmacology relating to pharmaceutical quality control; providing information on the research of medical products relating to pharmaceutical quality control | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Illimis Therapeutics, Inc.
- Other trademarks owned by Illimis Therapeutics, Inc.
- Other trademarks owned by Illimis Therapeutics, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named ILLIMIS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 31, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 6, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 6, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 4, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 4, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 4, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 10, 2023 | LIME | LIMITATION FROM THE IB EXAMINED AND ENTERED | — |
| Apr 25, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 18, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 18, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 5, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 5, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 29, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 21, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 11, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 7, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 7, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 7, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 27, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 27, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 13, 2023 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Jan 1, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 31, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 29, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 14, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 10, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 9, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |